[go: up one dir, main page]

DK3072507T3 - Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi - Google Patents

Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi Download PDF

Info

Publication number
DK3072507T3
DK3072507T3 DK16169413.8T DK16169413T DK3072507T3 DK 3072507 T3 DK3072507 T3 DK 3072507T3 DK 16169413 T DK16169413 T DK 16169413T DK 3072507 T3 DK3072507 T3 DK 3072507T3
Authority
DK
Denmark
Prior art keywords
glucocorticode
pharmaceutical compositions
substitution therapy
therapy
substitution
Prior art date
Application number
DK16169413.8T
Other languages
English (en)
Inventor
Stanko Skrtic
Jörgen Johnsson
Hans Lennernäs
Thomas Hedner
Gudmundur Johannsson
Original Assignee
Shire Viropharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Viropharma Llc filed Critical Shire Viropharma Llc
Application granted granted Critical
Publication of DK3072507T3 publication Critical patent/DK3072507T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
DK16169413.8T 2004-04-22 2005-04-21 Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi DK3072507T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56420504P 2004-04-22 2004-04-22
SE0401031A SE0401031D0 (sv) 2004-04-22 2004-04-22 A new glucocorticoid replacement therapy
EP05735076.1A EP1744730B1 (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for glucocorticoid replacement therapy

Publications (1)

Publication Number Publication Date
DK3072507T3 true DK3072507T3 (da) 2021-02-08

Family

ID=35197481

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16169413.8T DK3072507T3 (da) 2004-04-22 2005-04-21 Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi
DK05735076.1T DK1744730T3 (da) 2004-04-22 2005-04-21 Farmaceutiske sammensætninger til glucocorticoid-substitutionsterapi

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05735076.1T DK1744730T3 (da) 2004-04-22 2005-04-21 Farmaceutiske sammensætninger til glucocorticoid-substitutionsterapi

Country Status (25)

Country Link
US (3) US8425937B2 (da)
EP (2) EP1744730B1 (da)
JP (2) JP5149618B2 (da)
CN (2) CN103006592B (da)
AU (1) AU2005235370B2 (da)
BR (1) BRPI0510044B8 (da)
CA (1) CA2564000C (da)
CY (2) CY1118275T1 (da)
DK (2) DK3072507T3 (da)
ES (2) ES2857600T3 (da)
HR (2) HRP20161380T1 (da)
HU (2) HUE030546T2 (da)
IL (2) IL178776A (da)
LT (2) LT1744730T (da)
ME (1) ME02584B (da)
MX (2) MX344197B (da)
NZ (1) NZ585340A (da)
PL (2) PL1744730T3 (da)
PT (2) PT3072507T (da)
RS (2) RS55198B1 (da)
SE (1) SE0401031D0 (da)
SG (1) SG188081A1 (da)
SI (1) SI3072507T1 (da)
WO (1) WO2005102271A2 (da)
ZA (1) ZA200609680B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
MXPA06012088A (es) * 2004-04-22 2007-08-14 Duocort Ab Composiciones farmaceuticas para terapia aguda con glucocorticoides.
WO2007067494A1 (en) * 2005-12-06 2007-06-14 Monosol Rx, Llc Topical film compositions for delivery of actives
FR2926722B1 (fr) * 2008-01-25 2010-09-03 Substipharm Dev Formulation pharmaceutique appropriee pour la preparation de comprimes orodispersibles de prednisolone
ES2358158T3 (es) * 2008-07-21 2011-05-06 Dr. Falk Pharma Gmbh Formulación farmacéutica para el tratamiento del tracto digestivo superior.
US20120183610A1 (en) 2009-04-07 2012-07-19 Lennernaes Hans glucocorticoid therapy
KR20130099815A (ko) * 2010-05-20 2013-09-06 듀오코트 파마 아베 글루코코르티코이드에 기초한 조성물의 약량학 및 투여
GB201119985D0 (en) * 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
JP2014086673A (ja) 2012-10-26 2014-05-12 Mitsubishi Electric Corp モノリシック集積回路
SG11201503440UA (en) 2012-11-02 2015-06-29 Heart Care Western Australia Pty Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
HUE054663T2 (hu) * 2013-04-16 2021-09-28 Murray & Poole Entpr Ltd A kolicicin tartós kibocsátási készítményei és az annak alkalmazás módszerei
CA2909370A1 (en) * 2013-04-16 2014-10-23 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition
MX348595B (es) * 2013-08-02 2017-06-21 Laboratorio Raam De Sahuayo S A De C V Composicion farmaceutica con agentes antiinflamatorios y proceso de produccion.
HUE042009T2 (hu) 2013-12-23 2019-06-28 Dr Falk Pharma Gmbh Optimalizált gyógyszerkiszerelés a nyelõcsõ gyulladásos elváltozásainak kezelésére
ES2906778T3 (es) * 2015-03-30 2022-04-20 Corcept Therapeutics Inc Uso de antagonistas del receptor de glucocorticoides en combinación con glucocorticoides para tratar la insuficiencia suprarrenal
CN107115308B (zh) * 2016-02-23 2021-02-23 天津金耀集团有限公司 一种氢化可的松双相缓释片剂组合物
RU2748437C2 (ru) * 2019-10-28 2021-05-25 Федеральное государственное бюджетное учреждение науки Институт цитологии Российской академии наук (ИНЦ РАН) Производное гидрокортизона в качестве средства для лечения болезни Альцгеймера
FR3116439B1 (fr) * 2020-11-26 2023-08-04 Laboratoire Dielen Comprimé pelliculé contenant au moins un principe actif, adapté à l’administration par voie orale dudit au moins un principe actif chez des sujets humains

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2260384C3 (de) * 1972-12-09 1979-11-29 Hoechst Ag, 6000 Frankfurt Oral zu applizierendes Corticosteroid-Präparat
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5314697A (en) 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
NZ278678A (en) * 1994-01-31 1998-03-25 Yamanouchi Pharma Co Ltd Compressed moulded tablet with quick disintegration/dissolution in the mouth, mixture of low and high moldable saccharides as carriers
US5534263A (en) 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
DE19718012C1 (de) 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6156743A (en) 1999-10-18 2000-12-05 Whitcomb; John E. Method of decreasing fatigue
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
US20030190360A1 (en) * 2001-03-13 2003-10-09 Baichwal Anand R. Chronotherapeutic dosage forms containing glucocorticosteroid and methods of treatment
IL157921A0 (en) * 2001-03-15 2004-03-28 Enteron Pharmaceuticals Inc Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
GB0119848D0 (en) 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
CA2474190A1 (en) 2002-02-07 2003-08-14 Pharmacia Corporation Pharmaceutical dosage form for mucosal delivery
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
MXPA06012088A (es) 2004-04-22 2007-08-14 Duocort Ab Composiciones farmaceuticas para terapia aguda con glucocorticoides.
GB0623740D0 (en) 2006-11-28 2007-01-10 Diurnal Ltd Treatment of disease
US20120183610A1 (en) 2009-04-07 2012-07-19 Lennernaes Hans glucocorticoid therapy
KR20130099815A (ko) 2010-05-20 2013-09-06 듀오코트 파마 아베 글루코코르티코이드에 기초한 조성물의 약량학 및 투여

Also Published As

Publication number Publication date
CN1942176A (zh) 2007-04-04
DK1744730T3 (da) 2016-08-29
JP2007533698A (ja) 2007-11-22
MX344197B (es) 2016-12-08
MXPA06012011A (es) 2007-04-16
JP2012236846A (ja) 2012-12-06
EP1744730B1 (en) 2016-08-03
US20130129823A1 (en) 2013-05-23
SG188081A1 (en) 2013-03-28
PL1744730T3 (pl) 2017-01-31
PT3072507T (pt) 2021-02-23
PT1744730T (pt) 2016-10-07
HUE030546T2 (en) 2017-05-29
CA2564000A1 (en) 2005-11-03
WO2005102271A2 (en) 2005-11-03
ZA200609680B (en) 2008-08-27
EP1744730A2 (en) 2007-01-24
AU2005235370A1 (en) 2005-11-03
RS61501B1 (sr) 2021-03-31
LT3072507T (lt) 2021-02-25
BRPI0510044A (pt) 2007-10-16
CY1118275T1 (el) 2017-06-28
US10583146B2 (en) 2020-03-10
LT1744730T (lt) 2016-10-25
NZ585340A (en) 2012-04-27
EP3072507A1 (en) 2016-09-28
EP3072507B1 (en) 2020-12-23
HRP20210348T1 (hr) 2021-04-16
CA2564000C (en) 2013-07-02
PL3072507T3 (pl) 2021-07-19
CN103006592A (zh) 2013-04-03
RS55198B1 (sr) 2017-01-31
BRPI0510044B8 (pt) 2021-05-25
CN103006592B (zh) 2016-03-02
HK1179525A1 (zh) 2013-10-04
CY1124074T1 (el) 2022-03-24
BRPI0510044B1 (pt) 2019-01-29
ES2857600T3 (es) 2021-09-29
US20080187586A1 (en) 2008-08-07
SE0401031D0 (sv) 2004-04-22
IL227375A (en) 2017-08-31
US8425937B2 (en) 2013-04-23
ES2600556T3 (es) 2017-02-09
HUE053248T2 (hu) 2021-06-28
WO2005102271A3 (en) 2006-08-03
SI3072507T1 (sl) 2021-04-30
JP5681679B2 (ja) 2015-03-11
IL178776A (en) 2013-10-31
IL178776A0 (en) 2007-02-11
HRP20161380T1 (hr) 2016-12-02
AU2005235370B2 (en) 2011-06-09
US20140242167A1 (en) 2014-08-28
JP5149618B2 (ja) 2013-02-20
CN1942176B (zh) 2013-09-18
ME02584B (me) 2017-06-20

Similar Documents

Publication Publication Date Title
BRPI0511900A (pt) composições farmacêuticas
CY2014030I1 (el) Θεραπευτικες συνθεσεις που περιλαμβανουν ingenol-3-angelate
DK3424932T3 (da) Bronophthalider til terapeutisk anvendelse
HUS1400051I1 (hu) Lurazidont tartalmazó gyógyászati készítmény
NO20075628L (no) Farmasøytiske formuleringer
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
BRPI0715712A2 (pt) Composição farmacêutica
BRPI0719393A2 (pt) Composição farmacêutica
GB0409703D0 (en) Pharmaceutical compositions
DK1962873T3 (da) Farmaceutiske sammensætninger omfattende oxalat-reducerende bakterier
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
GB0408308D0 (en) Pharmaceutical compositions
DK3072507T3 (da) Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi
BRPI0720234A2 (pt) Composição farmacêutica
BRPI0716445A2 (pt) composiÇço farmacÊutica
ZA200702418B (en) Taste-masking Pharmaceutical compositions
DK1725218T3 (da) Farmaceutisk sammensætning omfattende pimobendan
ATE453384T1 (de) Neue dosierformulierung
EP1937255A4 (en) PHARMACEUTICAL COMPOSITION
EP1805154A4 (en) PHARMACEUTICAL COMPOSITIONS
EP1862184A4 (en) PHARMACEUTICAL COMPOSITION
ITMI20041447A1 (it) Composizione farmaceutica comprendente gabapentina
ITMI20040943A1 (it) Composizione farmaceutica cicatrizzante
GB0407351D0 (en) Pharmaceutical compositions
EP1747205A4 (en) PHARMACEUTICAL COMPOSITIONS